On the recordSeptember 16, 2015
If we are successful in getting this pathway to biosimilars moving then my fear is with a product sitting on the market that could cost 30 percent less we are going to be behind this avalanche of pharmaceutical advertising that will keep the market away from the biosimilars.
Source
congress.gov




